PRIME-HFrEF Trial: a randomized, double-blind, multi-dose umbilical cord-derived mesenchymal stem cell regimen for heart failure.

Signal Transduct Target Ther · 2026 · PMC13021951 · PMID 41888108

Europe PMC DOI

hedged sentence

0.0910

closest p · 1.8× alpha

0.0910

boldest claim

The sentences

did not reach statistical significanceP = 0.091so close (0.05 < p ≤ 0.1)

However, positive antinuclear antibody (ANA) titers (1:300 or 1:1000) were observed in 6 of 20 UC-MSC recipients (30.0%), compared to 1 of 19 patients (5.3%) in the placebo group, a difference that did not reach statistical significance (P = 0.091).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.